Fate Therapeutics
FATE
116 hedge funds and large institutions have $893M invested in Fate Therapeutics in 2018 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 43 increasing their positions, 26 reducing their positions, and 14 closing their positions.
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
83% more capital invested
Capital invested by funds: $488M → $893M (+$405M)
65% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 26
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
14% more call options, than puts
Call options by funds: $2.77M | Put options by funds: $2.43M
13% more funds holding
Funds holding: 103 → 116 (+13)
5.85% more ownership
Funds ownership: 81.42% → 87.27% (+5.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$43.8M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$17.8M |
| 3 |
DM
Deerfield Management
New York
|
+$13.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$12M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$8.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.22M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$2.04M |
| 3 |
Morgan Stanley
New York
|
-$1.85M |
| 4 |
6CM
683 Capital Management
New York
|
-$1.11M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$907K |
FATE Hedge Fund Activity: Q3 2018 in Review
116 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2018, worth a combined $893M — up 83% from $488M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new FATE positions and 14 closed out — a net gain of 13 holders — while 43 added to existing stakes and 26 trimmed.
The largest buyer was Redmile Group, adding an estimated $43.8M. The largest seller was Millennium Management, cutting an estimated $6.22M.
- 116 institutional investors held Fate Therapeutics (FATE) as of Q3 2018, up from 103 in Q2 2018.
- Funds reported $893M of Fate Therapeutics stock for Q3 2018, up 83% quarter-over-quarter.
- 27 funds opened new Fate Therapeutics positions in Q3 2018 and 14 closed out, a net change of +13 holders.
- The largest Fate Therapeutics buyer in Q3 2018 was Redmile Group, an estimated $43.8M added.
- The largest Fate Therapeutics seller in Q3 2018 was Millennium Management, an estimated $6.22M sold.
Based on aggregated 13F filings for Q3 2018.